Delos Wealth Advisors’s AbbVie ABBV Stock Holding History

Delos Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.5K	Sell	200 -10	-5%	-$2.22K	0.02%	131
2025 Q4	$48K	Hold	210	–	–	0.03%	95
2025 Q3	$48.6K	Hold	210	–	–	0.03%	105
2025 Q2	$39K	Buy	+210	New	+$39K	0.03%	104
2025 Q1	–	Sell	-3	Closed	-$611	–	54
2024 Q4	$611	Hold	3	–	–	﹤0.01%	185
2024 Q3	$672	Sell	3 -83	-97%	-$15.5K	﹤0.01%	166
2024 Q2	$14.8K	Sell	86 -8	-9%	-$1.32K	0.01%	109
2024 Q1	$17.2K	Buy	94 +83	+755%	+$14.3K	0.02%	99
2023 Q4	$1.73K	Sell	11 -424	-97%	-$61.8K	﹤0.01%	142
2023 Q3	$63.9K	Hold	435	–	–	0.08%	61
2023 Q2	$58.6K	Hold	435	–	–	0.07%	62
2023 Q1	$69.3K	Hold	435	–	–	0.09%	56
2022 Q4	$70.3K	Hold	435	–	–	0.11%	53
2022 Q3	$58K	Hold	435	–	–	0.07%	56
2022 Q2	$67K	Buy	435 +1	+0.2%	+$153	0.07%	53
2022 Q1	$70K	Hold	434	–	–	0.07%	68
2021 Q4	$59K	Buy	434 +424	+4,240%	+$50.1K	0.06%	69
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	160
2021 Q2	$1K	Buy	+10	New	+$1.13K	﹤0.01%	153

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Delos Wealth Advisors's ABBV Position: Q1 2026 in Review

Delos Wealth Advisors reduced its AbbVie (ABBV) stake by 4.8% in Q1 2026, selling an estimated $2.22K and leaving 200 shares worth $43.5K. The position accounts for 0.02% of the portfolio, ranked #131.

Delos Wealth Advisors first reported a position in ABBV in Q2 2021 and has held it in 19 quarters since. The position peaked at $70.3K in Q4 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Delos Wealth Advisors held 200 shares of AbbVie worth $43.5K as of Q1 2026.
Delos Wealth Advisors sold 10 AbbVie shares in Q1 2026, an estimated $2.22K.
AbbVie made up 0.02% of Delos Wealth Advisors's portfolio in Q1 2026, its #131 holding.
Delos Wealth Advisors first reported a position in AbbVie in Q2 2021 and has held it in 19 quarters since.
Delos Wealth Advisors's AbbVie position peaked at $70.3K in Q4 2022.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Delos Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.